CPT code 95012 denotes measurement of fractional exhaled nitric oxide (FeNO), a noninvasive diagnostic test that quantifies airway inflammation commonly used in evaluation and management of asthma and other inflammatory airway conditions. Nationally, FeNO testing matters for targeted disease management, medication monitoring, and objective assessment of airway eosinophilic inflammation, supporting clinical decisions about anti-inflammatory therapy.

Key payers covered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of clinical context for FeNO testing, the typical sites where the test is performed, and payer coverage considerations. The publication outlines benchmarks and utilization patterns where available, recent policy or coding updates relevant to FeNO measurement, and practical billing considerations such as common modifiers and service line placement. Where input data is not provided, the report notes "Data not available in the input." This national-level summary is intended to inform clinicians, practice managers, and coding professionals about the purpose of CPT code 95012, typical clinical use, and the payer landscape that affects reimbursement and access.